Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 46 AL 60

Stem-cell challenges in the treatment of Alzheimer's disease: a long way from bench to bedside

Fan X, Sun D, Tang X, Cai Y, Yin ZQ, Xu H.

Med Res Rev. 2014 Sep;34(5):957-78. doi: 10.1002/med.21309. Epub 2014 Feb 5.

Arginine metabolising enzymes as targets against Alzheimers' disease

Whiteley CG.

Neurochem Int. 2014 Feb;67:23-31. doi: 10.1016/j.neuint.2014.01.013. Epub 2014 Feb 4.

Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease

Bennett DA, Yu L, De Jager PL.

Biochem Pharmacol. 2014 Apr 15;88(4):617-30. doi: 10.1016/j.bcp.2014.01.037. Epub 2014 Feb 6.

Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis

Bandyopadhyay S, Rogers JT.

Biochem Pharmacol. 2014 Apr 15;88(4):486-94. doi: 10.1016/j.bcp.2014.01.032. Epub 2014 Feb 7.

Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

Ponnayyan Sulochana S, Sharma K, Mullangi R, Sukumaran SK.

Biomed Chromatogr. 2014 Nov;28(11):1431-90. doi: 10.1002/bmc.3116. Epub 2014 Feb 11.

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

Talbot K, Wang HY.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S12-25. doi: 10.1016/j.jalz.2013.12.007.

Vaccination against Alzheimer disease: an update on future strategies

Fettelschoss A, Zabel F, Bachmann MF.

Hum Vaccin Immunother. 2014;10(4):847-51. doi: 10.4161/hv.28183. Epub 2014 Feb 17.

Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group.

Phytomedicine. 2014 May 15;21(6):888-92. doi: 10.1016/j.phymed.2014.01.003. Epub 2014 Feb 16.

D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease

Kumar J, Sim V.

Prion. 2014 Jan-Feb;8(1):119-24. doi: 10.4161/pri.28220.

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan R, Vassar R.

Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD005380. doi: 10.1002/14651858.CD005380.pub5.

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: a comprehensive review of evidences

Saravanaraman P, Chinnadurai RK, Boopathy R.

Rev Neurosci. 2014;25(2):231-46. doi: 10.1515/revneuro-2013-0056.

Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease

Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.

Curr Drug Targets. 2014 May;15(5):539-50. doi: 10.2174/1389450115666140226112321.

Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies

Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P.

ScientificWorldJournal. 2014 Jan 22;2014:174282. doi: 10.1155/2014/174282. eCollection 2014.

Retinoids as potential targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Biochem Behav. 2014 May;120:117-23. doi: 10.1016/j.pbb.2014.02.016. Epub 2014 Feb 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias